Jasper van Grunsven

Executive Vice President and Chief Pain and New Product Planning Officer · Vertex Pharmaceuticals

Biopharmaceuticals

Jasper van Grunsven leads Vertex Pharmaceuticals’ pain franchise and global new product planning. He joined Vertex after commercial leadership assignments at Amgen in Europe, Asia and the United States.

Last reviewed: Nov 2, 2026

Jasper van Grunsven

Executive Vice President and Chief Pain and New Product Planning Officer
Vertex Pharmaceuticals

Last Reviewed: November 2, 2026

Executive Summary

Jasper van Grunsven leads Vertex Pharmaceuticals’ pain franchise and global new product planning. He joined Vertex after commercial leadership assignments at Amgen in Europe, Asia and the United States.

Career Highlights

  • Joined Vertex in September 2026 to oversee acute and neuropathic pain and new product planning.
  • Led Amgen’s rare-disease business after earlier leadership of U.S. general medicine.
  • Built commercial capabilities spanning analytics, digital tools, patient support and field operations.

Professional Journey

Van Grunsven worked at Nycomed and Abbott/AbbVie before joining Amgen. Those earlier assignments included Dutch affiliate and European regional responsibilities, immunology commercial operations and integration projects.

He joined Amgen in 2013 as director of sales and marketing for its Netherlands affiliate and became general manager in early 2014. In that role, he coordinated reimbursement and launch work for five brands. He also served on the board of the Netherlands Association of Innovative Medicines, with work involving market access and regulatory pathways.

His subsequent Amgen roles included global marketing lead for Repatha and vice president of commercial innovation in the JAPAC region, based in Hong Kong. The regional assignment included launch work for Repatha and Prolia in China and Evenity in Japan, along with Otezla integration responsibilities.

Van Grunsven then became the founding vice president of global commercial capabilities. That organization brought together data analytics, digital capabilities, commercial operations, patient support and related functions. He later led U.S. general medicine and became senior vice president of rare disease, also overseeing global customer capabilities and customer data analytics.

After more than 13 years at Amgen, he joined Vertex in September 2026. His current responsibilities encompass the pain franchise, including acute and neuropathic pain, and global planning for new products.

Education

Van Grunsven holds a Master of Science in biomedical sciences from Maastricht University in the Netherlands.